These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33060077)

  • 1. Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial.
    Yuk HD; Jeong CW; Kwak C; Kim H; Moon KC; Ku JH
    BMJ Open; 2020 Oct; 10(10):e035530. PubMed ID: 33060077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial.
    Szabados B; Rodriguez-Vida A; Durán I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez-Vidal MJ; Suárez C; Linch M; Prendergast A; Tyson C; Mousa K; Castellano D; Powles T
    Eur Urol Oncol; 2021 Jun; 4(3):456-463. PubMed ID: 33612455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
    Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19).
    Petrausch U; Spahn M; Schneider M; Hayoz S; Rentsch CA; Rothschild S; Omlin A; Cathomas R
    BMJ Open; 2023 Jun; 13(6):e067634. PubMed ID: 37286312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an
    Satkunasivam R; Lim K; Teh BS; Guzman J; Zhang J; Farach A; Chen SH; Wallis CJ; Efstathiou E; Esnaola NF; Sonpavde GP
    Future Oncol; 2022 Aug; 18(25):2771-2781. PubMed ID: 35703113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial.
    Crabb S; Danson SJ; Catto JWF; McDowell C; Lowder JN; Caddy J; Dunkley D; Rajaram J; Ellis D; Hill S; Hathorn D; Whitehead A; Kalevras M; Huddart R; Griffiths G
    Trials; 2018 Apr; 19(1):216. PubMed ID: 29615077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery.
    Jackson-Spence F; Toms C; O'Mahony LF; Choy J; Flanders L; Szabados B; Powles T
    Future Oncol; 2023 Mar; 19(7):509-515. PubMed ID: 37082935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
    Funt SA; Lattanzi M; Whiting K; Al-Ahmadie H; Quinlan C; Teo MY; Lee CH; Aggen D; Zimmerman D; McHugh D; Apollo A; Durdin TD; Truong H; Kamradt J; Khalil M; Lash B; Ostrovnaya I; McCoy AS; Hettich G; Regazzi A; Jihad M; Ratna N; Boswell A; Francese K; Yang Y; Folefac E; Herr HW; Donat SM; Pietzak E; Cha EK; Donahue TF; Goh AC; Huang WC; Bajorin DF; Iyer G; Bochner BH; Balar AV; Mortazavi A; Rosenberg JE
    J Clin Oncol; 2022 Apr; 40(12):1312-1322. PubMed ID: 35089812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
    Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
    Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
    Thibault C; Elaidi R; Vano YA; Rouabah M; Braychenko E; Helali I; Audenet F; Oudard S
    Bull Cancer; 2020 Jun; 107(5S):eS8-eS15. PubMed ID: 32620213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
    Meeks JJ; Bellmunt J; Bochner BH; Clarke NW; Daneshmand S; Galsky MD; Hahn NM; Lerner SP; Mason M; Powles T; Sternberg CN; Sonpavde G
    Eur Urol; 2012 Sep; 62(3):523-33. PubMed ID: 22677572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
    Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
    Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype.
    Kim B; Lee C; Kim YA; Moon KC
    Front Oncol; 2020; 10():527385. PubMed ID: 33365265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
    Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
    J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study.
    Kitamura H; Hinotsu S; Tsukamoto T; Shibata T; Mizusawa J; Kobayashi T; Miyake M; Nishiyama N; Kojima T; Nishiyama H;
    Jpn J Clin Oncol; 2020 Dec; 50(12):1464-1469. PubMed ID: 32699909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemotherapy Before Radical Cystectomy: Why We Must Adhere?
    Calò B; Marchioni M; Sanguedolce F; Falagario UG; Chirico M; Carrieri G; Cormio L
    Curr Drug Targets; 2021; 22(1):14-21. PubMed ID: 32738871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy for muscle-invasive bladder cancer.
    Jain RK; Sonpavde G
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):603-614. PubMed ID: 32546025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.